Criteria for staging and indication of treatment in T-PLL
| Staging: at least 1 criterion defines active T-PLL (= indication for treatment) . | ||
|---|---|---|
| Disease-related constitutional symptoms | Significant fatigue: ECOG ≥2 | |
| Unintentional weight loss of >10% of normal body weight in ≤6 mo | ||
| Drenching night sweats, without evidence of infection | ||
| Fever greater than 38°C, without evidence of infection | ||
| Symptomatic bone marrow failure | Hemoglobin | <10 g/dL |
| Platelet count | <100 × 109/L | |
| Rapidly enlarging lymph nodes, spleen, and liver | >50% in 2 mo; diameter doubling <6 mo | |
| Symptomatic enlarged lymph node, spleen, or liver | ||
| Increasing lymphocytosis | If >30 × 109/L: >50% in 2 mo; lymphocyte doubling time <6 mo | |
| Extranodal involvement | Organ infiltration; peritoneal or pleural effusion, central nervous system involvement | |
| Staging: at least 1 criterion defines active T-PLL (= indication for treatment) . | ||
|---|---|---|
| Disease-related constitutional symptoms | Significant fatigue: ECOG ≥2 | |
| Unintentional weight loss of >10% of normal body weight in ≤6 mo | ||
| Drenching night sweats, without evidence of infection | ||
| Fever greater than 38°C, without evidence of infection | ||
| Symptomatic bone marrow failure | Hemoglobin | <10 g/dL |
| Platelet count | <100 × 109/L | |
| Rapidly enlarging lymph nodes, spleen, and liver | >50% in 2 mo; diameter doubling <6 mo | |
| Symptomatic enlarged lymph node, spleen, or liver | ||
| Increasing lymphocytosis | If >30 × 109/L: >50% in 2 mo; lymphocyte doubling time <6 mo | |
| Extranodal involvement | Organ infiltration; peritoneal or pleural effusion, central nervous system involvement | |